Vascular endothelial growth factor: Potential predictor of treatment response in major depression

References

• Bauer M, Pretorius H, Constant EL, Earley WR, Szamosi J, Brecher M. 2009. Extended-release quetiapine as adjunct to an antidepressant in patients with major depressive disorder: results of a randomized, placebo-controlled, double-blind study. J Clin Psychiatry. 70:540–549.
   PubMed Web of Science ®Google Scholar
• Berent D, Macander M, Szemraj J, Orzechowska A, Galecki P. 2014. Vascular endothelial growth factor A gene expression level is higher in patients with major depressive disorder and not affected by cigarette smoking, hyperlipidemia or treatment with statins. Acta Neurobiol Exp (Wars). 74:82–90.
   PubMed Web of Science ®Google Scholar
• Boldrini M, Hen R, Underwood MD, Rosoklija GB, Dwork AJ, Mann JJ, et al. 2012. Hippocampal angiogenesis and progenitor cell proliferation are increased with antidepressant use in major depression. Biol Psychiatry. 72:562–571.
   PubMed Web of Science ®Google Scholar
• Cao L, Jiao X, Zuzga DS, Liu Y, Fong DM, Young D, et al. 2004. VEGF links hippocampal activity with neurogenesis, learning and memory. Nat Genet. 36:827–835.
   PubMed Web of Science ®Google Scholar
• Carvalho LA, Torre JP, Papadopoulos AS, Poon L, Juruena MF, Markopoulo K, et al. 2013. Lack of clinical therapeutic benefit of antidepressants is associated overall activation of the inflammatory system. J Affect Disord. 148:136–140.
   PubMed Web of Science ®Google Scholar
• Clark-Raymond A, Meresh E, Hoppensteadt D, Fareed J, Sinacore J, Halaris A. 2014. Vascular Endothelial Growth Factor: a potential diagnostic biomarker for major depression. J Psychiatr Res. 59:22–27.
   PubMed Web of Science ®Google Scholar
• Clark-Raymond A, Halaris A. 2013. VEGF and Depression: A Comprehensive Assessment of Clinical Data. J Psychiatr Res. 47:1080–1087.
   PubMed Web of Science ®Google Scholar
• Cutler AJ, Montgomery SA, Feifel D, Lazarus A, Astrom M, Brecher M. 2009. Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled study. J Clin Psychiatry. 70:526–539.
   PubMed Web of Science ®Google Scholar
• Dalby RB, Elfving B, Pousen PH, Foldager L, Frandsen J, Videbech P, et al. 2013. Plasma brain-derived neurotrophic factor and prefrontal white matter integrity in late-onset depression and normal aging. Acta Psychiatr Scand. 128:387–396.
   PubMed Web of Science ®Google Scholar
• Dome P, Halmai Z, Dobos J, Lazary J, Gonda X, Kenessey I, et al. 2012. Investigation of circulating endothelial progenitor cells and angiogenic and inflammatory cytokines during recovery from an episode of major depression. J Affect Disord. 136:1159–1163.
   PubMed Web of Science ®Google Scholar
• Dome P, Telezi Z, Rihmer Z, Peter L, Dobos J, Kenessey I, et al. 2009. Circulating endothelial progenitor cells and depression: a possible novel link between heart and soul. Mol Psychiatry. 14:523–531.
   PubMed Web of Science ®Google Scholar
• Duman RS, Monteggia LM. 2006. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 59:1116–1127.
   PubMed Web of Science ®Google Scholar
• Elfving B, Buttenschon HN, Foldager L, Poulson PH, Grynderup MB, Hansen AM, et al. 2014. Depression and BMI influences the serum vascular endothelial growth factor level. Int J Neuropsychopharmacol. 17:1409–1417.
   PubMed Web of Science ®Google Scholar
• Elfving B, Plougmann PH, Wegener G. 2010. Differential brain, but not serum VEGF levels in a genetic rat model of depression. Neurosci Lett. 474:13–16.
   PubMed Web of Science ®Google Scholar
• Fava M, Davidson KG. 1996. Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am. 19:179–200.
   PubMed Web of Science ®Google Scholar
• Fornaro M, Rocchi G, Escelsior A, Contini P, Ghio M, Colicchio S, et al. 2013. VEGF plasma level variations in duloxetine-treated patients with major depression. J Affect Disord. 151:590–595.
   PubMed Web of Science ®Google Scholar
• Galecki P, Orzechowska A, Berent D, Talarowska M, Bobinska K, Galecka E, et al. 2013a. Vascular endothelial growth factor receptor 2 gene (KDR) polymorphisms and expression levels in depressive disorder. J Affect Disord. 147:144–149.
   PubMed Web of Science ®Google Scholar
• Galecki P, Galecka E, Maes M, Orzechowska A, Berent D, Talarowska M, et al. 2013b. Vascular endothelial growth factor gene (VEGFA) polymorphisms may serve as prognostic factors for recurrent depressive disorder development. Prog Neuropsychopharmacol Biol Psychiatry. 45:117–124.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Stiglin LE, Finkelstein SN, Berndt ER. 1993. The economic burden of depression in 1990. J Clin Psychiatry. 54:405–418.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Kessler RC, Birnbaum HG, Leong SA, Lowe SW, Berglund PA, et al. 2003. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry. 64:1465–1475.
   PubMed Web of Science ®Google Scholar
• Greenberg PE, Fournier AA, Sisitsky T, Pike CT, Kessler RC. 2015. The Economic Burden of Adults with Major depressive Disorder in the United States (2005 and 2010). J Clin Psychiatry. 76:155–162.
   PubMed Web of Science ®Google Scholar
• Halmai Z, Dome P, Dobos J, Gonda X, Szekely A, Sasvari-Szekely M, et al. 2013. Peripheral vascular endothelial growth factor level is associated with antidepressant treatment response: results of a preliminary study. J Affect Disord. 144:269–273.
   PubMed Web of Science ®Google Scholar
• Heine VM, Zareno J, Maslam S, Joëls M, Lucassen PJ. 2005. Chronic stress in the adult dentate gyrus reduces cell proliferation near the vasculature and VEGF and Flk-1 protein expression. Eur J Neurosci. 21:1304–1314.
   PubMed Web of Science ®Google Scholar
• Hirschfeld RM, Schatzberg AF. 1994. Long-term management of depression. Am J Med. 97:33S–38S.
   PubMed Web of Science ®Google Scholar
• Ibrahim L, Duncan W, Luckenbaugh DA, Yuan P, Machado-Viera R, Zarate CA. 2011. Rapid antidepressant changes with sleep deprivation in major depressive disorder are associated with changes in vascular endothelial growth factor (VEGF): A pilot study. Brain Res Bull. 86:129–133.
   PubMed Web of Science ®Google Scholar
• Iga J, Ueno S, Yamauchi K, Numata S, Tayoshi-Shibuya S, Kinouchi S, et al. 2006. Gene expression and association analysis of vascular endothelial growth factor in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry. 31:658–663.
   PubMed Web of Science ®Google Scholar
• Isung J, Aeinehband S, Mobarrez F, Martensson B, Nordstrom P, Asberg M, et al. 2012. Low vascular endothelial growth factor and interleukin-8 in cerebrospinal fluid of suicide attempters. Transl Psychiatry. 2:e196 Doi. 10.1038/tp.2012.123.
   PubMed Web of Science ®Google Scholar
• Isung J, Mobarrez F, Nordstrom P, Asberg M, Jokinen J. 2012. Low plasma vascular endothelial growth factor (VEGF) associated with completed suicide. World J Biol Psychiatry. 13:468–473.
   PubMed Web of Science ®Google Scholar
• Jin K, Zhu Y, Sun Y, Mao XO, Xie L, Greenberg DA. 2002. Vascular endothelial growth factor (VEGF) stimulates neurogenesis in vitro and in vivo. Proc Natl Acad Sci USA. 99:11946–11150.
   PubMed Web of Science ®Google Scholar
• Kahl KG, Bens S, Ziegler K, Rudolf S, Kordon A, Dibbelt L, et al. 2009. Angiogenic factors in patients with current major depressive disorder comorbid with borderline personality disorder. Psychoneuroendocrinology. 34:353–357.
   PubMed Web of Science ®Google Scholar
• Kessler RC, Berglund P, Demler O, Jin R, Koretz D, Merikangas KR, et al. 2003. The epidemiology of major depressive disorder: results from the National Comorbidity Survey Replication (NCS-R). JAMA. 289:3095–3105.
   PubMed Web of Science ®Google Scholar
• Kodama M, Fujioka T, Duman RS. 2004. Chronic olanzapine or fluoxetine administration increases cell proliferation in hippocampus and prefrontal cortex of adult rat. Biol Psychiatry. 56:570–580.
   PubMed Web of Science ®Google Scholar
• Kotan Z, Sarandöl E, Kırhan E, Özkaya G, Kırlı S. 2012. Serum brain-derived neurotrophic factor, vascular endothelial growth factor and leptin levels in patients with a diagnosis of severe major depressive disorder with melancholic features. Ther Adv Psychopharmacol. 2:65–74.
   PubMedGoogle Scholar
• Lee BH, Kim YK. 2012. Increased plasma VEGF levels in major depressive or manic episodes in patients with mood disorders. J Affect Disord. 136:181–184.
   PubMed Web of Science ®Google Scholar
• Liebowitz M, Lam RW, Lepola U, Datto C, Sweitzer D, Erikson H. 2010. Efficacy and tolerability of extended release quetapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trial. Depress Anxiety. 27:964–976.
   PubMed Web of Science ®Google Scholar
• Madsen TM, Treschow A, Bengzon J, Bolwig TG, Lindvall O, Tingström A. 2000. Increased neurogenesis in a model of electroconvulsive therapy. Biol Psychiatry. 47:1043–1049.
   PubMed Web of Science ®Google Scholar
• Malberg JE, Eisch AJ, Nestler EJ, Duman RS. 2000. Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J Neurosci. 20:9104–9110.
   PubMed Web of Science ®Google Scholar
• Minelli A, Maffioletti E, Bortolomasi M, Conca A, Zanardini R, Rillosi L, et al. 2014. Association between baseline serum vascular endothelial growth factor levels and response to electroconvulsive therapy. Acta Psychiatr Scand. 129:461–466.
   PubMed Web of Science ®Google Scholar
• Minelli A, Zanardini R, Abate M, Bortolomasi M, Gennarelli M, Bocchio-Chiavetto L. 2011. Vascular Endothelial Growth Factor (VEGF) serum concentration during electroconvulsive therapy (ECT) in treatment resistant depressed patients. Prog Neuropsychopharmacol Biol Psychiatry. 35:1322–1325.
   PubMed Web of Science ®Google Scholar
• McCloskey DP, Croll SD, Scharfman HE. 2005. Depression of synaptic transmission by Vascular Endothelial Growth Factor in adult rat hippocampus and evidence for increased efficacy after chronic seizures. J Neurosci. 25:8889–8897.
   PubMed Web of Science ®Google Scholar
• Rizvi SJ, Grima E, Tan M, Rotzinger S, Lin P, McIntyre RS, et al. 2014. Treatment-Resistant Depression in Primary Care Across Canada. Can J Psychiatry. 59:349–357.
   PubMed Web of Science ®Google Scholar
• Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. 2006. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 163:1905–1917.
   PubMed Web of Science ®Google Scholar
• Storkebaum E, Lambrechts D, Carmeliet P. 2004. VEGF: once regarded as a specific angiogenic factor, now implicated in neuroprotection. Bioessays. 26:943–954.
   PubMed Web of Science ®Google Scholar
• Sun R, Li N, Li T. 2012. VEGF regulates antidepressant effects of lamotrigine. Eur Neuropsychopharmacol. 2:424–430.
   Web of Science ®Google Scholar
• Takebyashi M, Hashimoto R, Hisaoka K, Tsuchioka M, Kunugi H. 2010. Plasma levels of vascular endothelial growth factor and fibroblast growth factor 2 in patients with major depressive disorders. J Neural Transm. 117:1119–1122.
   PubMed Web of Science ®Google Scholar
• Trivedi MH, Rush AJ, Wisniewski SR, Nierenberg AA, Warden D, Ritz L, et al. 2006. Evaluation of outcomes with citalopram for depression using measurement-based care in STAR*D: implications for clinical practice. Am J Psychiatry. 163:28–40.
   PubMed Web of Science ®Google Scholar
• Tsai SJ, Hong CJ, Lious YJ, Chen TJ, Chen ML, Hou SJ, et al. 2009. Haplotype analysis of single nucleotide polymorphisms in the vascular endothelial growth factor (VEGFA) gene and antidepressant treatment response in major depressive disorder. Psychiatry Res. 169:113–117.
   PubMed Web of Science ®Google Scholar
• Ventriglia M, Zanardini R, Pedrini L, Placentino A, Nielson MG, Gennarelli M, et al. 2009. VEGF serum levels in depressed patients during SSRI antidepressant treatment. Prog Neuropsychopharmacol Biol Psychiatry. 33:146–149.
   PubMed Web of Science ®Google Scholar
• Viikki M, Anttila S, Kampman O, Illi A, Huuhka M, Setälä-Soikkeli E, et al. 2010. Vascular endothelial growth factor (VEGF) polymorphism is associated with treatment resistant depression. Neurosci Lett. 477:105–108.
   PubMed Web of Science ®Google Scholar
• Warner-Schmidt JL, Duman RS. 2007. VEGF is an essential mediator of the neurogenic and behavioral actions of antidepressants. Proc Natl Acad Sci USA. 104:4647–4652.
   PubMed Web of Science ®Google Scholar
• Yarnold, PR, Soltysik, RC. 2005. Optimal Data Analysis: A Guidebook with software for Windows. Washington, DC: American Psychological Association.
   Google Scholar